Monitoring of indicators of physical availibility and socio-economic affordability of metformin hydrochloride medicines

Authors

DOI:

https://doi.org/10.15587/2519-4852.2022.263675

Keywords:

medicines, metformin, diabetes, physical availability, socio-economic affordability

Abstract

The aim of the study was to monitor the physical availability and socio-economic affordability of metformin hydrochloride medicines, which are used for the treatment of type II diabetes mellitus.

Materials and methods. Medical and technological documentation on the standardization of medical care for patients with type II diabetes, data from the State Register of Medicinal Products of Ukraine, software complex “Apteka” of the company “Morion” and data from the pharmaceutical market research analytical company “Pharmstandard” of the company “Morion” were used as research materials to determine indicators of physical availability and socio-economic affordability of metformin HCL medicines for the treatment of type II diabetes. Documentary, analytical methods, the method of marketing research and the method of logical summarization of data were used during the research.

Results. According to the results of the analysis of the medical and technological documentation on the standardization of medical care for diabetes mellitus (DM) type II and the State Register of Medicines of Ukraine, a number of characteristics were formed for Metformin HCL pharmaceuticals, namely: tablets or film-coated tablets in a dose of 500 mg, which are manufactured: Ukrainian manufacturers (full cycle of production); Ukrainian manufacturers of tablets in bulk (primary and secondary packaging) and foreign manufacturers. The specified characteristics became the basis for the further selection of several metformin HCL medicines in terms of determining their indicators of physical availability and socio-economic affordability. When determining the physical availability of metformin HCL medications, it was established that Ukrainian-made pharmaceuticals (full production cycle) are presented in the wholesale chain of the pharmaceutical market in full. According to the socio-economic indicator of the solvency adequacy of payment capacity, among the metformin HCL pharmaceuticals, the most economically justified are the Ukrainian-made pharmaceuticals, which are made from tablets in bulk according to the full production cycle. Only 1 medicine was singled out among foreign-made ones, which has the lowest indicator of solvency adequacy for various categories of the population.

Conclusions. Monitoring of indicators of physical availability and socio-economic affordability of metformin HCL medicines showed that the most economically justified for able-bodied people and people of retirement age is the use of the Ukrainian-made pharmaceuticals (full cycle and production from tablets in bulk) for the treatment of type II DM)

Supporting Agency

  • Ministry of Health of Ukraine with funds from the state budget on the topic “Toxico-pharmacological Study of Nitrosamines and Related Risk Assessment for the Regulatory System of Metformin Medicines” (state registration no.: 0122U002056).

Author Biographies

Oksana Ryshchenko, National University of Pharmacy

PhD, Assistant

Department of Social Pharmacy

Dmytro Lytkin, National University of Pharmacy

PhD, Vice-Director of Educational and Scientific Institute

Educational and Scientific Institute of Applied Pharmacy

Illya Podolsky, National University of Pharmacy

Doctor of Pharmaceutical Sciences, Associated Professor

Department of Medicinal Chemistry

Alina Volkova, National University of Pharmacy

PhD, Associate Professor

Department of Social Pharmacy

Inna Vladymyrova, National University of Pharmacy

Doctor of Pharmaceutical Science, Professor, Vice-rector for Scientific and Pedagogical Work

References

  1. Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V. et. al. (2019). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 41 (2), 255–323. doi: http://doi.org/10.1093/eurheartj/ehz486
  2. Flory, J., Lipska, K. (2019). Metformin in 2019. JAMA, 321 (19), 1926–1928. doi: http://doi.org/10.1001/jama.2019.3805
  3. Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry TsD 2 typu (2012). Nakaz MOZ Ukrainy No. 1118. 12.12.2012. Available at: https://zakon.rada.gov.ua/rada/show/v1118282-12#Text
  4. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes (2009). The National Collaborating Centre for Chronic Conditions. Available at: https://www.ncbi.nlm.nih.gov/books/NBK61842/
  5. Type 2 diabetes: National clinical guideline for management in primary and secondary care (2008). The National Collaborating Centre for Chronic Conditions. Available at: https://www.ncbi.nlm.nih.gov/books/NBK53885/
  6. Dahlén, A. D., Dashi, G., Maslov, I. O., Attwood, M. M., Jonsson, J., Trukhan, V., Schiöth, H. B. (2022). Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales. Frontiers in Pharmacology, 12. doi: http://doi.org/10.3389/fphar.2021.807548
  7. Litvinova, E., Posilkina, O., Kovalenko, S., Yeromenko, R., Bratishko, Y., Lisna, A. (2022). Status and analysis of trends in the metformin -based drug development: formation of the logistic system of scientific research. ScienceRise: Pharmaceutical Science, 2 (36), 37–45. doi: http://doi.org/10.15587/2519-4852.2022.255536
  8. Lv, Z., Guo, Y. (2020). Metformin and Its Benefits for Various Diseases. Frontiers in Endocrinology, 11. doi: http://doi.org/10.3389/fendo.2020.00191
  9. Vyshnytska, I. V., Trokhymchuk, V. V. (2018). Marketing analysis of some groups antidiabetic medicines, presented at pharmaceutical market of Ukraine. Farmatsevtychnyi Zhurnal, 2, 3–11. doi: http://doi.org/10.32352/0367-3057.2.17.01
  10. Salem, A., Men, P., Ramos, M., Zhang, Y.-J., Ustyugova, A., Lamotte, M. (2021). Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China. Journal of Comparative Effectiveness Research, 10 (6), 469–480. doi: http://doi.org/10.2217/cer-2020-0284
  11. Limwattananon, C., Waleekhachonloet, O. (2019). Access to and price trends of antidiabetic, antihypertensive, and antilipidemic drugs in outpatient settings of the Universal Coverage Scheme in Thailand. PLOS ONE, 14 (2), e0211759. doi: http://doi.org/10.1371/journal.pone.0211759
  12. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. Available at: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument
  13. Prohramnyi kompleks «Apteka». Available at: https://pharmbase.com.ua/ru/optovye-predlozheniya/
  14. Kotvitska, A. A., Volkova, A. V., Kubarieva, I. V., Cherkashyna, A. V., Korzh, Yu. V., Tereshchenko, L. V., Surikova, I. O.; Kotvitska, A. A. (Ed.). (2021). Sotsialna farmatsiia. Kharkiv: NFaU, 264.
  15. Kotvitska, A. A., Prokopenko, O. S. (2019). Monitoring of indicators of physical and socio-economic availability of medicines used for Parkinson’s disease treatment. Management, economy and quality assurance in pharmacy, 3 (59), 55–63. doi: http://doi.org/10.24959/uekj.19.15
  16. Nemchenko, A. S., Nazarkina, V. M., Panfilova, H. L. et. al.; Nemchenko, A. S. (Ed.) (2017). Orhanizatsiia ta ekonomika farmatsii. Ch. 1. Orhanizatsiia farmatsevtychnoho zabezpechennia naselennia. Kharkiv: NFaU: Zoloti storinky, 327.
  17. Panfilova, H. L. Koefitsiient adekvatnosti platospromozhnosti. Available at: https://www.pharmencyclopedia.com.ua/article/8076/koeficiyent-adekvatnosti-platospromozhnosti
  18. Doslidzhennia farmatsevtychnoho rynku Ukrainy analitychnoi kompanii «Farmstandart» kompanii «Morion». Available at: http://www.pharmstandart.com.ua/login
  19. Kotvitska, A., Volkova, A., Korzh, I., Surikova, I. (2021). Comparative analysis of indicators that determine the effectiveness of the implementation of socio-economic determinants of health in Europe and Ukraine. ScienceRise: Pharmaceutical Science, 3 (31), 34–41. doi: http://doi.org/10.15587/2519-4852.2021.235787
  20. Savych, A. O., Pavliuk, B. V. (2022). Marketing analysis of the pharmaceutical market of antidiabetic drugs in Ukraine. Current Issues in Pharmacy and Medicine: Science and Practice, 15 (1), 80–85. doi: http://doi.org/10.14739/2409-2932.2022.1.252509
  21. Dermatis, Z., Lazakidou, A., Anastasiou, A., Liargovas, P. (2020). Analyzing Socio-Economic and Geographical Factors that Affect the Health of the Elderly. Journal of the Knowledge Economy, 12 (4), 1925–1948. doi: http://doi.org/10.1007/s13132-020-00691-9
  22. Kovalevska, I., Ruban, O., Volkova, A., Kotvitska, A., & Cherkashyna, A. (2022). The use of complex marketing analysis and QSPR methodology for the necessity of a drug development grounding for the treatment of type 2 diabetes mellitus with increased bioavailability. Pharmacia, 69 (2), 303–310. doi: http://doi.org/10.3897/pharmacia.69.e79179
  23. Zhu, L., She, Z.-G., Cheng, X., Qin, J.-J., Zhang, X.-J., Cai, J. et. al. (2020). Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metabolism, 31 (6), 1068–1077.e3. doi: http://doi.org/10.1016/j.cmet.2020.04.021
  24. Luo, P., Qiu, L., Liu, Y., Liu, X., Zheng, J., Xue, H. et. al. (2020). Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis. The American Journal of Tropical Medicine and Hygiene, 103 (1), 69–72. doi: http://doi.org/10.4269/ajtmh.20-0375
  25. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2018 (2017). Diabetes Care, 41 (Supplement_1), S13–S27. doi: http://doi.org/10.2337/dc18-s002
  26. Bramante, C. T., Ingraham, N. E., Murray, T. A., Marmor, S., Hovertsen, S., Gronski, J. et. al. (2021). Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis. The Lancet Healthy Longevity, 2 (1), e34–e41. doi: http://doi.org/10.1016/s2666-7568(20)30033-7
  27. Mishchenko, O. Ya., Kalko, K. O., Оstashko, V. F., Borysiuk, I. Yu., Rokun, D.-M. В., Ryshchenko, O. O., Bezdetko, N. V. (2021). Range analysis, socio-economic accessibility and consumption of fibrates on the pharmaceutical market of Ukraine during 2017–2020. Pharmacologyonline, 2, 650–656.
  28. Briukhanova, T., Lytkin, D., Zahaiko, A., Bondareva, A. (2021). The effect of nmda-receptor antagonist on carbohydrate and lipid metabolism markers in syrian golden hamsters under experimetal insulin resistance syndrome and diabetes mellitus. Problems of Endocrine Pathology, 78 (4), 72–79. doi: http://doi.org/10.21856/j-pep.2021.4.10
  29. Ghany, R., Palacio, A., Dawkins, E., Chen, G., McCarter, D., Forbes, E. et. al. (2021). Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 15 (2), 513–518. doi: http://doi.org/10.1016/j.dsx.2021.02.022
  30. Wander, P. L., Lowy, E., Beste, L. A., Tulloch-Palomino, L., Korpak, A., Peterson, A. C. et. al. (2021). Prior Glucose-Lowering Medication Use and 30-Day Outcomes Among 64,892 Veterans With Diabetes and COVID-19. Diabetes Care, 44 (12), 2708–2713. doi: http://doi.org/10.2337/dc21-1351

Downloads

Published

2022-08-29

How to Cite

Ryshchenko, O., Lytkin, D., Podolsky, I., Volkova, A., & Vladymyrova, I. (2022). Monitoring of indicators of physical availibility and socio-economic affordability of metformin hydrochloride medicines. ScienceRise: Pharmaceutical Science, (4 (38), 36–43. https://doi.org/10.15587/2519-4852.2022.263675

Issue

No. 4 (38) (2022)

Section

Pharmaceutical Science

License

Copyright (c) 2022 Oksana Ryshchenko, Dmytro Lytkin, Illya Podolsky, Alina Volkova, Inna Vladimirova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.